CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM
Cadrenal Therapeutics (Nasdaq: CVKD) has joined the Corporate Council of the Anticoagulation Forum (AC Forum), the largest professional organization of anticoagulation specialists. The company, which is developing tecarfarin, a new vitamin K antagonist for patients with implanted cardiac devices or rare cardiovascular conditions, will collaborate with AC Forum's 15,000 healthcare professional members to advance anticoagulation care quality and safety. This partnership aims to address unmet clinical needs, share research, and promote educational initiatives for improving patient outcomes on anticoagulants.
Cadrenal Therapeutics (Nasdaq: CVKD) è entrata a far parte del Consiglio Aziendale del Forum Anticoagulazione (AC Forum), la più grande organizzazione professionale per specialisti in anticoagulazione. L'azienda, che sta sviluppando tecarfarin, un nuovo antagonista della vitamina K per pazienti con dispositivi cardiaci impiantati o condizioni cardiovascolari rare, collaborerà con i 15.000 membri professionisti della salute dell'AC Forum per migliorare la qualità e la sicurezza delle cure anticoagulanti. Questa partnership ha l'obiettivo di affrontare le esigenze cliniche non soddisfatte, condividere ricerche e promuovere iniziative educative per migliorare i risultati dei pazienti sui farmaci anticoagulanti.
Cadrenal Therapeutics (Nasdaq: CVKD) se ha unido al Consejo Corporativo del Foro de Anticoagulación (AC Forum), la organización profesional más grande de especialistas en anticoagulación. La empresa, que está desarrollando tecarfarin, un nuevo antagonista de la vitamina K para pacientes con dispositivos cardíacos implantados o condiciones cardiovasculares raras, colaborará con los 15,000 miembros profesionales de la salud del AC Forum para mejorar la calidad y seguridad de la atención anticoagulante. Esta asociación tiene como objetivo abordar las necesidades clínicas no atendidas, compartir investigaciones y promover iniciativas educativas para mejorar los resultados de los pacientes con anticoagulantes.
Cadrenal Therapeutics (Nasdaq: CVKD)는 가장 큰 항응고 전문 조직인 항응고 포럼 (AC Forum)의 기업 자문위원회에 합류했습니다. 심장 장치가 이식된 환자나 희귀 심혈관 질환을 가진 환자를 위한 새로운 비타민 K 길항제인 tecarfarin을 개발 중인 이 회사는 AC 포럼의 15,000명 의료 전문가와 협력하여 항응고 치료의 품질과 안전성을 향상시킬 것입니다. 이 파트너십은 충족되지 않은 임상 요구를 해결하고, 연구를 공유하며, 항응고제에 대한 환자 결과를 개선하기 위한 교육 이니셔티브를 촉진하는 것을 목표로 합니다.
Cadrenal Therapeutics (Nasdaq: CVKD) a rejoint le Conseil des entreprises du Forum d'anticoagulation (AC Forum), la plus grande organisation professionnelle d'experts en anticoagulation. L'entreprise, qui développe tecarfarin, un nouvel antagoniste de la vitamine K pour les patients avec des dispositifs cardiaques implantés ou des conditions cardiovasculaires rares, collaborera avec les 15 000 membres professionnels de la santé de l'AC Forum pour améliorer la qualité et la sécurité des soins anticoagulants. Ce partenariat vise à répondre aux besoins cliniques non satisfaits, à partager des recherches et à promouvoir des initiatives éducatives pour améliorer les résultats des patients sous anticoagulants.
Cadrenal Therapeutics (Nasdaq: CVKD) ist dem Unternehmensrat des Antikoagulationsforums (AC Forum) beigetreten, der größten Berufsorganisation für Antikoagulationsspezialisten. Das Unternehmen, das tecarfarin entwickelt, einen neuen Vitamin-K-Antagonisten für Patienten mit implantierten Herzgeräten oder seltenen kardiovaskulären Erkrankungen, wird mit den 15.000 Mitgliedern des Gesundheitsdienstes des AC Forums zusammenarbeiten, um die Qualität und Sicherheit der Antikoagulationsversorgung zu verbessern. Diese Partnerschaft zielt darauf ab, unerfüllte klinische Bedürfnisse zu adressieren, Forschung zu teilen und Bildungsinitiativen zur Verbesserung der Patientenergebnisse bei Antikoagulanzien zu fördern.
- Strategic partnership with largest professional organization of anticoagulation specialists
- Access to network of 15,000 healthcare professionals for potential market penetration
- Enhanced visibility and credibility in the anticoagulation therapy space
- None.
Participation Reinforces Cadrenal's Commitment to Innovation, Education and Improved Patient Outcomes with Anticoagulation Therapy
The AC Forum is the largest professional organization of anticoagulation specialists, committed to advancing the quality and safety of chronic anticoagulation care globally. Through participation in the Corporate Council, Cadrenal Therapeutics will collaborate with the AC Forum as it works to identify and address unmet clinical needs, share cutting-edge research, and promote advocacy and educational initiatives for the organization's 15,000 healthcare professional members aimed at improving outcomes for patients on anticoagulants.
"Our membership in the AC Forum's Corporate Council reflects our shared commitment to transforming anticoagulation care," said Quang X. Pham, Chief Executive Officer of Cadrenal Therapeutics. "We look forward to partnering with the AC Forum and contributing to programs that advance safer, more effective care and inform about ongoing research and anticoagulation best practice guidelines."
Darren Triller, PharmD, Director of Strategic Initiatives at the Anticoagulation Forum, welcomed Cadrenal Therapeutics to the Corporate Council, saying: "We are excited to have Cadrenal Therapeutics join us in our mission to improve the quality of care for patients receiving antithrombotic therapies. We look forward to a productive partnership that will help us address the challenges in the anticoagulation landscape together."
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to offer safer, superior chronic anticoagulation for patients with implanted cardiac devices or rare cardiovascular conditions. Tecarfarin is anticipated to result in fewer adverse events such as strokes, heart attacks, bleeds and deaths than warfarin, the most commonly used anticoagulant for these patients despite its prevalent side effects, drug-to-drug interactions and frequent dosing changes. Tecarfarin received an orphan drug designation for advanced heart failure patients with implanted left ventricular assist devices (LVADs) as well as both orphan drug and fast-track status for end-stage kidney disease patients with atrial fibrillation. Cadrenal is planning pivotal clinical trials and pursuing clinical and commercial partnerships. The company's plans also include studying tecarfarin in patients with mechanical heart valves experiencing anticoagulation difficulties. Visit www.cadrenal.com to learn more.
About the Anticoagulation Forum
The Anticoagulation Forum has led advancements in thrombosis-related care for over three decades. With more than 15,000 members across 3,000 healthcare institutions, the AC Forum is dedicated to enhancing the safety and quality of care for over 1 million patients annually. Through education, thought leadership, and partnerships with industry leaders, the AC Forum shapes the future of anticoagulation management to ensure the best outcomes for patients.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-joins-corporate-council-of-anticoagulation-forum-302283944.html
SOURCE Cadrenal Therapeutics, Inc.
FAQ
What is the significance of Cadrenal Therapeutics (CVKD) joining the Anticoagulation Forum?
What product is Cadrenal Therapeutics (CVKD) developing for anticoagulation?
What is the Anticoagulation Forum that Cadrenal Therapeutics (CVKD) joined?
